Latest Exclusive Distribution Agreements News

Mayne Pharma Group Limited reported a robust FY25 with a 5% revenue increase to A$408.1 million and a 105% surge in underlying EBITDA, driven by strong growth in Women’s Health and strategic acquisitions in Dermatology.

Memphasys Limited reported a net loss of AUD 4.94 million for FY25 while accelerating commercial efforts for its Felix System and advancing its RoXsta diagnostics platform.

DXN Limited reported a 49% surge in revenue to $16 million for FY25, driven by strong modular data centre contracts and a new Data Centre as a Service division, despite a slight increase in net loss to $2.31 million.

Sprintex Limited reported a 26% revenue increase for FY25 but also a 37% rise in net loss, as it accelerates global expansion through key distribution deals and manufacturing upgrades.

Stealth Group Holdings has reported a record-breaking 2025 financial year, with sales climbing 27.6% and net profit more than doubling. The company is accelerating its growth strategy, aiming to more than double sales by 2028.

Shaver Shop Group Limited reported a slight dip in FY25 sales but achieved record gross margins and EBIT growth, driven by its successful Transform-U private brand launch. Early FY26 trading shows promising sales momentum.

Shaver Shop Group reported a slight dip in FY25 sales but achieved record gross margins and EBIT growth, driven by its new private label and exclusive brand deals.

MaxiPARTS Limited reported a robust FY25 with revenues climbing 9.5% to $267.1 million and net profit soaring 179% to $7.7 million, underpinned by strategic acquisitions and margin improvements.

SportsHero Limited has entered the Southeast Asian mobile gaming market by signing an exclusive distribution agreement with Yes2Games, bringing globally popular titles like Fruit Ninja and Jetpack Joyride to Indonesia, the Philippines, Thailand, and Malaysia.

Aumake Limited reported a remarkable 213% surge in quarterly cash receipts, driven by exclusive distribution agreements and strategic cost reductions, setting the stage for profitability in FY26.

OncoSil Medical has reported a record 20% quarterly increase in dose sales and secured $8.7 million in new capital, underpinning its clinical and commercial expansion in pancreatic cancer treatment.

Osteopore Limited reports a three-fold increase in craniofacial implant sales within a year of signing an exclusive distribution deal with Zimmer Biomet, signaling strong early traction across key global markets.